NASDAQ — Healthcare: Manufacturing, Biotechnology: Pharmaceutical Preparations
skyebioscience.comSkye Bioscience will present expanded preclinical data on nimacimab, a peripherally restricted CB1 inhibitor, at the American Diabetes Association (ADA) conference in June 2025. The data highlight nimacimab’s potential in obesity treatment, including its efficacy alone and in combination with tirzepatide, a GLP-1/GIP agonist. Preclinical results show nimacimab’s superior potency versus monlunabant and comparable weight loss to established therapies in diet-induced obesity models. Nimacimab is being developed as a differentiated biologic for metabolic disorders, with a mechanism designed to avoid central nervous system side effects associated with other CB1 inhibitors.
conference talkSkye Bioscience expects to release initial data from its Phase 2a study in obesity, showcasing the potential of nimacimab, in late Q3/early Q4 2025.
clinical readoutSkye Bioscience is conducting a Phase 2 clinical trial evaluating the efficacy of Nimacimab, a monoclonal antibody, administered weekly alone and in combination with semaglutide (Wegovy) for obesity and overweight patients with comorbidities. The study, involving 120 participants, is expected to complete on January 1, 2026. The trial is currently active but not recruiting. Nimacimab is being investigated as a novel therapeutic for weight management, potentially expanding Skye's metabolic disease portfolio.
trial completion